Rockwell Medical Inc  

(Public, NASDAQ:RMTI)   Watch this stock  
Find more results for RMTI
7.98
-0.02 (-0.25%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.83 - 8.14
52 week 5.47 - 15.91
Open 8.02
Vol / Avg. 0.00/371,100.00
Mkt cap 410.16M
P/E     -
Div/yield     -
EPS -0.31
Shares 51.53M
Beta 1.78
Inst. own 34%
Aug 2, 2016
Q2 2016 Rockwell Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 2, 2016
Rockwell Medical Inc Annual Shareholders Meeting
May 20, 2016
Rockwell Medical Inc Annual Shareholders Meeting (Estimated)
May 10, 2016
Q1 2016 Rockwell Medical Inc Earnings Call
May 10, 2016
Q1 2016 Rockwell Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -35.40% -26.05%
Operating margin -33.80% -27.28%
EBITD margin - -25.80%
Return on average assets -21.87% -15.52%
Return on average equity -31.59% -22.01%
Employees 300 -
CDP Score - -

Address

30142 S Wixom Rd
WIXOM, MI 48393-3440
United States - Map
+1-248-9609009 (Phone)
+1-248-9609119 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

Officers and directors

Robert L. Chioini Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Thomas E. Klema CPA, MBA Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Ajay Gupta M.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Raymond D. Pratt M.D. Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Robin L. Smith M.D. Director
Age: 51
Bio & Compensation  - Reuters
Patrick J. Bagley Independent Director
Age: 50
Bio & Compensation  - Reuters
Ronald D. Boyd Independent Director
Age: 52
Bio & Compensation  - Reuters
Kenneth L. Holt Independent Director
Age: 62
Bio & Compensation  - Reuters